Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kropf

Showing results (841-850 of 862) with videos related to

Pageof 87
Sort By:
Journal of the American Chemical Society|December 16, 2025
Unravelling the Stability Stressors of Atomically Dispersed Fe-N-C Oxygen Reduction CatalystsXiaohong Xie, Boyang Li, Pan Xu, et al.
Nature|January 21, 2021
A stable low-temperature H<sub>2</sub>-production catalyst by crowding Pt on α-MoCXiao Zhang, Mengtao Zhang, Yuchen Deng, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Nature|October 9, 2024
Overconfidence in climate overshootCarl-Friedrich Schleussner, Gaurav Ganti, Quentin Lejeune, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
Pageof 87

Showing results (841-850 of 862) with videos related to

Sort By:
Pageof 87
Journal of the American Chemical Society|December 16, 2025
Unravelling the Stability Stressors of Atomically Dispersed Fe-N-C Oxygen Reduction CatalystsXiaohong Xie, Boyang Li, Pan Xu, et al.
Nature|January 21, 2021
A stable low-temperature H<sub>2</sub>-production catalyst by crowding Pt on α-MoCXiao Zhang, Mengtao Zhang, Yuchen Deng, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Nature|October 9, 2024
Overconfidence in climate overshootCarl-Friedrich Schleussner, Gaurav Ganti, Quentin Lejeune, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
Pageof 87